- <![CDATA[Biomarker-Driven Treatment Decisions and Managing Progression After Frontline Immunotherapy]]><![CDATA[Upfront biomarker testing reshapes endometrial cancer care, guiding targeted and immune therapy—and exposing gaps in second-line options.]]>onclive · 2mo ago↗ source
- Merck KGaA's clients are stockpiling due to Iran war, supporting guidance boostMerck KGaA appears to have a big-picture view of how the Iran war is affecting the pharma industry so far. The German company is seeing an uptick in demand for its lab equipment products as ...Endpoints · 2mo ago↗ source
- <![CDATA[Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Cancer]]><![CDATA[Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.]]>